Form D · Biotechnology
Fluxa, Inc.
Glendale, CA · CIK 0001849807
Offering snapshot reported Mar 10, 2021 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 24, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 10, 2021 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-391739
Source: Form D, filed Mar 10, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Miller | Director, Executive |
| Sudheesh Narayanan | Director, Executive |
| John Nita | Director |
| Suraj Pai | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
500 N Brand Blvd Suite 2000
Glendale, CA, 91203
Glendale, CA, 91203